

Letter to the Editor

Tacrolimus formulations in de novo kidney transplantation: Evidence from a paired kidney study



Formulaciones de tacrolimus en el trasplante renal de novo: evidencia de un estudio con riñones emparejados

Dear Editor,

Tacrolimus is the cornerstone of immunosuppressive therapy in kidney transplantation, but its pharmacokinetic variability and narrow therapeutic window present challenges for optimal dosing and long-term graft survival.¹ Extended-release formulations, such as LCPT (Envarsus®) and ER-Tac (Advagraf®), have been developed to improve adherence and bioavailability.^{2,3} However, direct comparative studies using paired kidneys from the same donor are scarce. Here, we present a prospective, paired, open-label study comparing the efficacy and safety of LCPT and ER-Tac in de novo kidney transplant recipients.

Methods

We included 108 adult recipients of deceased donor kidney transplantation (DDKT) at a single center (Málaga, Spain). Each donor provided kidneys to two recipients, one assigned to LCPT and the other to ER-Tac, minimizing donor-related confounding. All patients received standard triple immunosuppression (tacrolimus, mycophenolic acid, steroids). Clinical and laboratory data were collected at baseline and regular intervals up to 48 weeks. Renal function, acute rejection (clinical and subclinical), pharmacokinetics, and safety (including infection and post-transplant diabetes) were assessed. Protocol biopsies were performed at three months in a subset of patients.

Results

Baseline characteristics

Both groups were well matched for recipient and donor demographics (Table 1).

Renal function

Mean serum creatinine and estimated glomerular filtration rate (eGFR) were similar between groups throughout follow-up. At week 4, eGFR was 45 mL/min/1.73 m² (LCPT) vs. 41 mL/min/1.73 m² (ER-Tac; $p = 0.256$); at week 48, 49 vs. 51 mL/min/1.73 m² ($p = 0.638$).

Acute rejection

Clinical acute rejection occurred in 23.4% (LCPT) vs. 28.3% (ER-Tac; $p = 0.817$). Subclinical rejection on protocol biopsy was observed in 61% (LCPT) vs. 80% (ER-Tac; $p = 0.405$).

Pharmacokinetics

LCPT required significantly lower total daily doses (TDD) than ER-Tac at all time points (week 48: 0.05 vs. 0.08 mg/kg; $p = 0.006$).

Table 1

Basal donors and recipients' characteristics.

	LCPT group (n = 54)	ER-Tac group (n = 54)	p-Value
Recipient characteristics			
Age, ys.	58 ± 11	55 ± 12	0.325
Sex (female), n (%)	18 (33)	27 (50)	0.118
Race, n (%)			
Caucasian	49 (90.7)	48 (88.9)	0.842
Black	1 (1.9)	2 (3.7)	
Arabic	4 (7.4)	4 (7.4)	
Pre-Tx diabetes, n (%)	13 (24)	8 (14)	0.184
Retransplant, n (%)	8 (14)	8 (14)	1
cPRA >50%, n (%)	10 (18)	9 (16)	0.801
Induction, n (%)			
No	4 (7.4)	7 (13)	0.409
ATG	24 (44.5)	27 (50)	
Basiliximab	26 (48.1)	20 (37)	
DGF, n (%)	16 (29)	18 (33)	0.775
CIT, h	13.2 ± 4.0	12.9 ± 3.9	0.760
CMV status of the recipient, n (%)			
CMV-negative	7 (13)	12 (22.2)	0.062
CMV-positive	43 (79.6)	42 (77.8)	
CMV-unknown	4 (7.4)	0 (0)	
Number of incompatibilities (A-B-C-DR-DQ)	6.8 ± 2.0	6.7 ± 1.7	0.971
Donor characteristics			
Age, ys.	58 ± 11	58 ± 11	1
Sex (female), n (%)	17 (31)	17 (31)	1
Diabetes mellitus, n (%)	4 (7)	4 (7)	1
Hypertension, n (%)	22 (40)	22 (40)	1
Creatinine, mg/dl	0.7 ± 0.3	0.7 ± 0.3	1
Stroke death, n (%)	29 (53)	29 (53)	1
CMV status of the donors, n (%)			
CMV-negative	7 (13)	7 (13)	1
CMV-positive	37 (68.5)	37 (68.5)	
CMV-unknown	10 (18.5)	10 (18.5)	

Data are shown as mean and standard deviation or median and interquartile range. Abbreviations: cPRA: calculated panel reactive antibody; ATG: anti-thymocyte globulin; DGF: delayed graft function; CIT: cold ischemia time; Tx: transplant; CMV: cytomegalovirus.




Fig. 1. (A) Tacrolimus TDD. Symbols indicating statistically significant differences between groups: *: $p < 0.001$; **: $p < 0.001$; ***: $p < 0.001$; †: $p < 0.001$; ††: $p < 0.001$; ‡: $p < 0.001$; ‡‡: $p = 0.01$; #: $p = 0.006$. (B) Trough concentration of tacrolimus. Symbols indicating statistically significant differences between groups: *: $p = 0.007$; ‡: $p = 0.04$. (C) Bioavailability of tacrolimus. Symbols indicating statistically significant differences between groups: *: $p = 0.006$; **: $p = 0.005$; ***: $p = 0.001$; †: $p = 0.001$; ‡: $p = 0.001$; #: $p = 0.001$. The data are showed as mean \pm standard deviation. Abbreviations: TCT: trough concentration of tacrolimus; TDD: total daily dose.

LCPT achieved higher trough concentrations early post-transplant (days 2 and 7; $p = 0.007$ and $p = 0.04$, respectively), with higher bioavailability (Fig. 1).

Safety

Incidence of post-transplant diabetes was 27.8% (LCPT) vs. 35.2% (ER-Tac; $p = 0.407$). Rates of CMV and BK virus infection were numerically lower in the LCPT group. Patient and graft survival were comparable.

Discussion

Our paired-kidney analysis demonstrates that LCPT offers significant pharmacokinetic advantages over ER-Tac, with lower required doses and higher early bioavailability, while maintaining similar efficacy and safety. These findings are consistent with previous studies showing improved bioavailability and reduced dose requirements with LCPT.^{4–7} The observed trend toward reduced subclinical rejection and improved early renal function with LCPT may be clinically relevant, given the association of early subclinical inflammation with long-term graft loss.^{8,9}

Both formulations were well tolerated, with similar rates of adverse events. The lower infection rates and numerically reduced post-transplant diabetes in the LCPT group align with the hypothesis that improved pharmacokinetics may translate into fewer complications.¹⁰

Limitations include the single-center design and limited sample size for protocol biopsies. Nonetheless, the paired-kidney methodology strengthens the comparative analysis by minimizing donor variability.

Conclusion

LCPT provides superior pharmacokinetic properties with a lower daily dose and higher early bioavailability compared to ER-Tac, without compromising efficacy or safety. Larger, multicenter studies are warranted to confirm these findings and evaluate long-term outcomes.

CRediT authorship contribution statement

V.L. and D.H. participated in designing, data analysis, writing original draft preparation and funding acquisition. J.P.G., M.L., J.A.T., C.G., C.P., T.V. and P.R.E. participated in data collection and in writing review of the manuscript. All authors agreed with the final document.

Institutional review board statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by de Provincial Ethics and Clinical Research Committee of Malaga (Cei Provincial de Malaga) (protocol code: 11/2017/PI13 and date of approval: 28 November 2017).

Informed consent statement

Informed consent was obtained from all subjects involved in the study.

Funding

This study was partly funded by grants from the Instituto de Salud Carlos III, Madrid, Spain (PI17/02043, ICI21/00042, and RICORS Network RD21/0005/0012), FONDOS FEDER and FIISC (PFIISC23/12).

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments


We are grateful to the kidney transplant team at our center for their participation in the study, and to Maria Romero (Trialance, S.C.C.L.) for providing medical writing support.

Data availability

Data are available on request due to privacy restrictions. The data presented in this study are available on request from the corresponding author. In compliance with Spanish Organic Law 15/1999, the data are not publicly available.

References

- Lim MA, Kohli J, Bloom RD. Immunosuppression for kidney transplantation: where are we now and where are we going? *Transplant Rev (Orlando)*. 2017;31:10–7, <http://dx.doi.org/10.1016/j.trre.2016.10.006>
- Grinyó JM, Petruzzelli S. Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations. *Expert Rev Clin Immunol*. 2014;10:1567–79, <http://dx.doi.org/10.1586/1744666x.2014.983903>
- Oberbauer R, Bestard O, Furian L, Maggiore U, Pascual J, Rostaing L, et al. Optimization of tacrolimus in kidney transplantation: new pharmacokinetic perspectives. *Transplant Rev (Orlando)*. 2020;34:100531, <http://dx.doi.org/10.1016/j.trre.2020.100531>
- Fernandez Rivera C, Calvo Rodríguez M, Poveda JL, Pascual J, Crespo M, Gomez G, et al. Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study. *Clin Transplant*. 2022;36:e14550, <http://dx.doi.org/10.1111/ctr.14550>
- Budde K, Bunnapradist S, Grinyó JM, Ciechanowski K, Denny JE, Silva HT, et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. *Am J Transplant*. 2014;14:2796–806, <http://dx.doi.org/10.1111/ajt.12955>
- Bunnapradist S, Ciechanowski K, West-Thielke P, Mulgaonkar S, Rostaing L, Vasudev B, et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. *Am J Transplant*. 2013;13:760–9, <http://dx.doi.org/10.1111/ajt.12035>
- Tremblay S, Nigro V, Weinberg J, Woodle ES, Alloway RR. A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study. *Am J Transplant*. 2017;17:432–42, <http://dx.doi.org/10.1111/ajt.13935>
- Mehta R, Bhusal S, Randhawa P, Sood P, Cherukuri A, Wu C, et al. Short-term adverse effects of early subclinical allograft inflammation in kidney transplant recipients with a rapid steroid withdrawal protocol. *Am J Transplant*. 2018;18:1710–7, <http://dx.doi.org/10.1111/ajt.14627>
- Hernández D, Alonso-Titos J, Vázquez T, León M, Caballero A, Cobo MA, et al. Clinical relevance of corticosteroid withdrawal on graft histological lesions in low-immunological-risk kidney transplant patients. *J Clin Med*. 2021;10, <http://dx.doi.org/10.3390/jcm10092005>
- Willuweit K, Frey A, Hörster A, Saner F, Herzer K. Real-world administration of once-daily MeltDose® prolonged-release tacrolimus (LCPT) allows for dose reduction of tacrolimus and stabilizes graft function following liver transplantation. *J Clin Med*. 2020;10, <http://dx.doi.org/10.3390/jcm10010124>

Verónica López^{a,1,*}, Juan Pablo Gámez^a, Myriam León^{b,1}, Juana Alonso-Titos^a, Cristina Gutiérrez^a, Carolina Polo^a, Teresa Vázquez^a, Pedro Ruiz-Esteban^{a,2}, Domingo Hernández ^{c,2}

^a Nephrology Department, Hospital Regional Universitario de Málaga, Universidad de Málaga, Instituto Biomédico de Investigación de Málaga (IBIMA)-Plataforma BIONAND, RICORS2040 (RD21/0005/0012 and RD24/0004/0026), Málaga, Spain

^b Pathology Department, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA)-Plataforma BIONAND, RICORS2040 (RD21/0005/0012 and RD24/0004/0026), Málaga, Spain

^c Nephrology Department, Hospital Universitario de Canarias, Instituto de Tecnologías Biomédicas-Universidad La Laguna, RICORS2040 (RD21/0005/0012 and RD24/0004/0025), Tenerife, Spain

* Corresponding author.

E-mail address: verolopezjim@yahoo.es (V. López).

¹ These authors contributed equally to this work.

² These authors shared senior authorship.